Mutagenic activity of antileprosy drugs and their derivatives.
We tested the mutagenic activity of antileprosy drugs (clofazimine, ethionamide, prothionamide, prothionamide-S-oxide, rifampin, and dapsone and many of its derivatives) using the Ames Salmonella/microsome assay system. None of these, including N-acetylated and N-hydroxylated derivatives of dapsone, were found to be positive with or without metabolic activation of this test. However, the sulfoxide and sulfide analogs of dapsone were found to be mutagenic with metabolic activation. These two analogs could not be detected in pharmaceutical preparations of dapsone (less than 0.01%), nor could they be found (in either unconjugated or conjugated form) in urine from volunteers taking a single oral dose of 50 mg of dapsone or from patients receiving daily oral doses of 100 mg of dapsone. Also, urine concentrates from volunteers taking 50 mg of dapsone did not exhibit mutagenic activity in the Ames screen. These results indicate that patients receiving antileprosy therapy with clofazimine, dapsone, ethionamide, prothionamide, and/or rifampin are not being exposed to mutagenic (and thereby possible carcinogenic) drugs.
D002991:Clofazimine / Q000633:toxicity; D005000:Ethionamide / Q000633:toxicity; D007917:Leprostatic Agents / Q000633:toxicity*; D009152:Mutagenicity Tests; D011515:Prothionamide / Q000031:analogs & derivatives / Q000633:toxicity; D012293:Rifampin / Q000633:toxicity
D007917:Leprostatic Agents; C033377:prothionamide-S-oxide; D011515:Prothionamide; D002991:Clofazimine; D005000:Ethionamide; D012293:Rifampin